Demographics of the transplanted leukemia patients
| Variable . | ALL . | AML . | ||
|---|---|---|---|---|
| Total (n = 323) . | Total (n = 1086) . | Donor with KIR B–content score 0 or 1 (n = 748) . | Donor with KIR B–content score ≥ 2 (n = 338) . | |
| Median age, y (range) | 18.5 (8-55) | 38.9 (1-70) | 39.0 (1-70) | 38.6 (1-68) |
| Race | ||||
| White | 261 (81) | 757 (70) | 512 (68) | 245 (72) |
| Nonwhite | 62 (19) | 329 (30) | 236 (32) | 93 (28) |
| Karnofsky score | ||||
| 90-100 | 232 (72) | 666 (61) | 460 (62) | 206 (61) |
| 10-80 | 91 (28) | 329 (30) | 227 (30) | 102 (30) |
| Unknown | 91 (8) | 61 (8) | 30 (9) | |
| Disease status when transplanted* | ||||
| Early | 80 (25) | 290 (27) | 200 (27) | 90 (27) |
| Intermediate | 159 (49) | 349 (32) | 232 (31) | 117 (35) |
| Advanced | 84 (26) | 447 (41) | 316 (42) | 131 (39) |
| Disease risk by cytogenetics | ||||
| Low | 0 (0) | 120 (11) | 75 (10) | 45 (13) |
| Intermediate | 133 (41) | 471 (43) | 341 (46) | 130 (38) |
| High | 68 (21) | 232 (21) | 164 (22) | 68 (20) |
| Unknown | 122 (38) | 263 (24) | 168 (22) | 95 (28) |
| Donor:recipient match for HLA-A, B, C, DRB1, and DQB1 | ||||
| 10/10 allele matched | 148 (46) | 539 (50) | 374 (50) | 165 (49) |
| 9/10 | 60 (19) | 301 (28) | 212 (28) | 89 (26) |
| 8/10 | 55 (17) | 158 (15) | 106 (14) | 52 (15) |
| Less than 8/10 | 60 (19) | 88 (8) | 56 (8) | 32 (10) |
| CMV serostatus | ||||
| Donor −/recipient − | 127 (39) | 331 (30) | 233 (31) | 98 (29) |
| Donor +/recipient − | 80 (25) | 144 (13) | 92 (12) | 52 (15) |
| Donor + or −/recipient + | 111 (34) | 578 (53) | 398 (53) | 180 (53) |
| Data missing | 5 (2) | 33 (3) | 25 (3) | 9 (3) |
| Graft type | ||||
| Bone marrow | 301 (93) | 641 (59) | 429 (57) | 212 (63) |
| Peripheral blood progenitor cells | 22 (7) | 445 (41) | 319 (43) | 126 (37) |
| Variable . | ALL . | AML . | ||
|---|---|---|---|---|
| Total (n = 323) . | Total (n = 1086) . | Donor with KIR B–content score 0 or 1 (n = 748) . | Donor with KIR B–content score ≥ 2 (n = 338) . | |
| Median age, y (range) | 18.5 (8-55) | 38.9 (1-70) | 39.0 (1-70) | 38.6 (1-68) |
| Race | ||||
| White | 261 (81) | 757 (70) | 512 (68) | 245 (72) |
| Nonwhite | 62 (19) | 329 (30) | 236 (32) | 93 (28) |
| Karnofsky score | ||||
| 90-100 | 232 (72) | 666 (61) | 460 (62) | 206 (61) |
| 10-80 | 91 (28) | 329 (30) | 227 (30) | 102 (30) |
| Unknown | 91 (8) | 61 (8) | 30 (9) | |
| Disease status when transplanted* | ||||
| Early | 80 (25) | 290 (27) | 200 (27) | 90 (27) |
| Intermediate | 159 (49) | 349 (32) | 232 (31) | 117 (35) |
| Advanced | 84 (26) | 447 (41) | 316 (42) | 131 (39) |
| Disease risk by cytogenetics | ||||
| Low | 0 (0) | 120 (11) | 75 (10) | 45 (13) |
| Intermediate | 133 (41) | 471 (43) | 341 (46) | 130 (38) |
| High | 68 (21) | 232 (21) | 164 (22) | 68 (20) |
| Unknown | 122 (38) | 263 (24) | 168 (22) | 95 (28) |
| Donor:recipient match for HLA-A, B, C, DRB1, and DQB1 | ||||
| 10/10 allele matched | 148 (46) | 539 (50) | 374 (50) | 165 (49) |
| 9/10 | 60 (19) | 301 (28) | 212 (28) | 89 (26) |
| 8/10 | 55 (17) | 158 (15) | 106 (14) | 52 (15) |
| Less than 8/10 | 60 (19) | 88 (8) | 56 (8) | 32 (10) |
| CMV serostatus | ||||
| Donor −/recipient − | 127 (39) | 331 (30) | 233 (31) | 98 (29) |
| Donor +/recipient − | 80 (25) | 144 (13) | 92 (12) | 52 (15) |
| Donor + or −/recipient + | 111 (34) | 578 (53) | 398 (53) | 180 (53) |
| Data missing | 5 (2) | 33 (3) | 25 (3) | 9 (3) |
| Graft type | ||||
| Bone marrow | 301 (93) | 641 (59) | 429 (57) | 212 (63) |
| Peripheral blood progenitor cells | 22 (7) | 445 (41) | 319 (43) | 126 (37) |
Values are n (%) unless otherwise noted.
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; and CMV, cytomegalovirus.
Disease status was defined as early (first complete remission), intermediate (second or higher complete remission), and advanced (first relapse, second or higher relapse, primary induction failure).